|Positive WB detected in||NIH/3T3 cells|
|Positive IP detected in||NIH/3T3 cells|
|Positive IHC detected in||human lung cancer tissue, human ovary tumor tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Sample-dependent, check data in validation data gallery|
10576-1-AP targets RPN2 in WB, IP, IHC,ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||RPN2 fusion protein Ag0862|
|Full Name||ribophorin II|
|Calculated molecular weight||69 kDa|
|Observed molecular weight||68-69 kDa|
|GenBank accession number||BC003560|
|Gene ID (NCBI)||6185|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
RPN2 (Ribophorin II), an integral rough ER membrane glycoprotein, is part of an N-oligosaccharyl transferase complex and is involved in translocation and the maintenance of the structural uniqueness of the rough ER. RPN2 expression has been reported to be significantly associated with solid cancers, including breast cancer, esophageal squamous cell carcinoma, colorectal cancer, and lung squamous cell carcinoma.
Onco Targets Ther
Downregulation of ribophorin II suppresses tumor growth, migration, and invasion of nasopharyngeal carcinoma.
Onco Targets Ther
RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis via the PI3K-Akt Pathway.